Oncology Medical Billing Services in Houston
Oncology billing is among the most financially complex and compliance-intensive specialties in medical revenue cycle management — encompassing chemotherapy drug administration, infusion therapy, injectable biologics, radiation oncology, and high-stakes prior authorization workflows governed by strict NCCI bundling rules and payer-specific oncology drug policies. MedVoice delivers expert oncology medical billing services in Houston, supporting medical oncology practices, hematology-oncology groups, infusion centers, and radiation oncology departments across the Houston metropolitan area. We navigate Medicare, Medicaid, and all major commercial payer oncology drug coverage policies to protect reimbursement for every chemotherapy administration, immunotherapy infusion, and oncology E/M service your practice delivers.
Proven Performance, Tangible Results
These results reflect MedVoice’s performance within oncology and hematology billing environments across Houston and the Texas Medical Center corridor.
98%
Clean Claim Rate
Oncology drug and infusion claims pass payer edits at 98% first-pass rate through J-code accuracy validation, NCCI bundling compliance, and prior authorization status verification before submission.
40%
Reduction in A/R Days
Proactive follow-up on high-value chemotherapy drug claims and prior authorization management reduce outstanding A/R by 40% for Houston oncology practices.
98%
Coding Accuracy
Certified oncology coders apply correct chemotherapy administration CPT codes, J-codes for injectable drugs, and infusion sequencing rules at a 98% accuracy rate across all oncology services.
15%
Increase in Revenue Collection
Optimized oncology drug billing, infusion administration coding, and denial recovery generate a 15% increase in net collections for Houston oncology practices.
Challenges We Solve for Oncology Practices in Houston
Oncology billing combines high-cost chemotherapy J-codes with complex infusion administration sequencing rules, NCCI bundling edits for concurrent services, and payer-specific prior authorization requirements for biologics and targeted therapies — all while managing oral chemotherapy parity, port access billing, and radiation oncology concurrent service compliance. Expert oncology denial management and drug administration coding accuracy are essential to protecting high-value oncology practice revenue.
Chemotherapy Drug Coding and J-Code Accuracy
Infusion Administration Sequencing and Bundling Errors
Prior Authorization for Biologics and Targeted Therapies
Oral Chemotherapy Parity Compliance
Port Access and Catheter Placement Charge Capture
Modifier -59 and -JW Drug Wastage Application Errors
Radiation Oncology Concurrent Service Billing
OCM Value-Based Oncology Billing Complexity
Why Oncology Billing Requires Specialized Expertise
Oncology billing demands precise knowledge of chemotherapy drug J-codes, infusion administration sequencing rules under NCCI, and payer-specific oncology drug coverage policies that vary significantly across Medicare, Medicaid, and commercial plans in Houston. Accurate billing requires in-depth expertise in concurrent infusion coding, oral chemotherapy parity laws, port and catheter access charge capture, radiation oncology technical and professional component billing, and prior authorization management for high-cost biologic and immunotherapy agents.
- Chemotherapy administration CPT coding including IV push (96409), infusion first hour (96413), each additional hour (96415), and subcutaneous/IM (96401–96402)
- J-code accuracy for injectable chemotherapy, immunotherapy, and biologic agents including dose-based and per-vial drug billing
- Infusion sequencing rules under NCCI for concurrent hydration, antiemetic, and chemotherapy administration on the same date of service
- Prior authorization management for targeted therapies, checkpoint inhibitors, and high-cost biologic oncology drugs
- Oral chemotherapy parity compliance under Texas insurance law and commercial payer policies for oral antineoplastic agents
- Port and central venous catheter access billing, insertion (36561), and maintenance charge capture for Houston infusion centers
- Radiation oncology billing including simulation (77261–77263), treatment planning (77295–77321), and delivery codes (77385–77402) for Houston cancer centers
MedVoice ensures every oncology service is billed accurately and compliantly, optimizing oncology revenue cycle management in Houston.
Common Diagnoses We Frequently Bill For (ICD-10 Codes)
Accurate ICD-10 oncology coding is critical — an unspecified malignancy code or missing metastasis documentation can trigger medical necessity denials for high-cost chemotherapy and immunotherapy drugs.
- Malignant neoplasm of breast, unspecified — C50.919
- Non-small cell lung cancer, unspecified — C34.10
- Malignant neoplasm of colon, unspecified — C18.9
- Malignant neoplasm of prostate — C61
- Non-Hodgkin lymphoma, unspecified type — C85.90
- Chronic lymphocytic leukemia, not having achieved remission — C91.10
- Acute myeloid leukemia, without FAB classification, not in remission — C92.00
- Malignant neoplasm of pancreas, unspecified — C25.9
- Malignant neoplasm of ovary — C56.9
- Malignant neoplasm of rectosigmoid junction — C19
- Secondary malignant neoplasm of liver — C78.7
- Malignant neoplasm of thyroid gland — C73
- Multiple myeloma — C90.00
- Secondary malignant neoplasm of lung — C78.00
- Nausea and vomiting due to antineoplastic chemotherapy — R11.2
Common Procedures & Billing Codes We Support
Precise chemotherapy administration CPT coding, J-code drug billing, and infusion sequencing compliance are essential for protecting reimbursement on high-value oncology services in Houston.
Evaluation & Management
- Office visit, new patient, high complexity — 99205
- Office visit, established patient, high complexity — 99215
- Chemotherapy, IV infusion, first hour — 96413
- Chemotherapy, IV infusion, each additional hour — 96415
- Chemotherapy, IV push, single drug — 96409
- Chemotherapy, subcutaneous/IM injection — 96401
- Therapeutic infusion, first hour — 96365
- Therapeutic infusion, each additional hour — 96366
- Hydration infusion, first 31 minutes — 96360
- Central venous catheter, implanted port, insertion — 36561
- Bone marrow biopsy — 38221
- Bone marrow aspiration — 38220
- PET scan — 78816
Who We Support
Our oncology billing solutions in Houston are tailored for:
Medical Oncology and Hematology Practices
Hospital-Based Cancer Centers
Outpatient Infusion Centers
Radiation Oncology Departments
Surgical Oncology Practices
Gynecologic Oncology Specialists
Pediatric Oncology Programs
Multi-Specialty Cancer Care Groups
Compliance & Documentation Accuracy
Oncology billing is subject to CMS chemotherapy drug coverage policies, NCCI bundling edits for concurrent infusion services, OIG audit priorities targeting chemotherapy upcoding and J-code drug billing accuracy, and payer-specific prior authorization requirements for biologics and immunotherapy agents. MedVoice maintains continuous compliance monitoring against Texas Medicaid oncology drug policies, commercial payer oncology coverage guidelines, and oral chemotherapy parity requirements to protect your Houston practice from audit exposure.
We ensure compliance with:
- HIPAA Privacy and Security Rules for oncology patient records, chemotherapy orders, and drug administration documentation
- CMS Part B drug coverage policies and Average Sales Price (ASP) pricing for injectable chemotherapy and biologic agents
- NCCI edits governing infusion administration sequencing and concurrent chemotherapy service bundling rules
- OIG high-risk billing areas including chemotherapy drug upcoding, J-code accuracy, and drug wastage billing with modifier -JW
- Texas oral chemotherapy parity law and commercial payer parity compliance for oral antineoplastic agents
- Prior authorization requirements for targeted therapies, checkpoint inhibitors, and biosimilar substitution policies
Benefits of Outsourcing Oncology Billing to MedVoice
Houston oncology practices that outsource to MedVoice consistently achieve faster reimbursement on high-cost chemotherapy drug claims, lower denial rates on biologic prior authorizations, and stronger financial performance than those managing billing in-house.
- 15% increase in revenue collection through accurate J-code drug billing and infusion administration charge capture
- 40% reduction in A/R days with dedicated oncology claim follow-up and real-time ERA/EOB posting
- 98% clean claim submission rate driven by J-code accuracy and NCCI infusion sequencing compliance
- Under 3% denial rate with oncology coding expertise and 24-hour resubmission turnaround
- Prior authorization management for biologics, immunotherapy, and targeted therapy agents to prevent treatment delays
- Free EHR and Practice Management Software integration for seamless chemotherapy order charge capture
- HIPAA-compliant systems with full audit trail for oncology drug administration records
- Dedicated oncology billing specialist with hematology-oncology expertise for your Houston practice
FAQ – Oncology Billing Solutions for Healthcare Practices in Houston
How does MedVoice reduce claim denials for oncology practices in Houston?
MedVoice reduces oncology claim denials through specialty-specific pre-submission scrubbing that checks J-code accuracy for chemotherapy drugs, NCCI infusion sequencing compliance for concurrent services, prior authorization status for biologic agents, and modifier -JW drug wastage documentation before claims are submitted. Our Houston-focused oncology denial team maintains a denial rate under 3% by resolving root causes — including drug coverage disputes and medical necessity appeals — not just resubmitting rejected claims.
What CPT and J-codes does MedVoice handle for oncology billing?
MedVoice handles the full oncology billing range, including chemotherapy administration (96401, 96409, 96413, 96415), therapeutic infusion (96365–96368), hydration (96360–96361), J-codes for all major chemotherapy and biologic agents, port insertion (36561), bone marrow procedures (38220, 38221), and oncology E/M codes (99202–99215). Our certified oncology coders apply correct modifiers, infusion sequencing rules, and NCCI-compliant code combinations.
Does MedVoice handle prior authorization for oncology biologics in Houston?
Yes — MedVoice manages the complete prior authorization workflow for high-cost oncology biologics, checkpoint inhibitors, targeted therapies, and biosimilar agents across Medicare, Medicaid, and all major commercial payers in Houston. We track authorization status, expiration dates, and coverage criteria to prevent treatment delays and drug administration denials, and we manage appeals for denied oncology drug coverage requests.
How quickly can a Houston oncology practice onboard with MedVoice?
Most Houston oncology practices complete MedVoice onboarding in 5–10 business days, including EHR integration with chemotherapy order charge capture workflows, J-code drug formulary setup, payer credentialing review, and prior authorization workflow configuration. Our onboarding team handles the full transition with zero interruption to your billing cycle, and you’ll be assigned a dedicated oncology billing specialist from day one.
What makes oncology medical billing more complex than general billing?
Oncology billing combines high-cost J-code drug billing with complex infusion administration sequencing rules under NCCI, concurrent service bundling for chemotherapy plus hydration plus antiemetics on the same date, prior authorization requirements for every biologic and targeted therapy agent, and oral chemotherapy parity compliance — all while managing drug wastage documentation, port access billing, and radiation oncology technical/professional component splitting. The financial stakes per claim are significantly higher than general practice billing, making coding accuracy and denial management critical for Houston oncology practice financial performance.
Request a Free Oncology Billing Audit Today
MedVoice’s free oncology billing audit delivers a comprehensive review of your chemotherapy administration coding accuracy, J-code drug billing compliance, infusion sequencing errors, and revenue recovery opportunities — with no obligation. Within 30 days of onboarding, Houston oncology providers consistently report reduced claim denials on chemotherapy drug claims, accelerated reimbursements, and measurable improvements in net collections. Partner with the leading oncology medical billing services provider in Houston and start seeing results immediately.
